SNS-595
Potential for Advanced Hematologic and Solid Malignancies
SNS-595 is a replication-dependent DNA-damaging agent that induces an irreversible G2 arrest and apoptosis. As a result, cancer cells, which are typically proliferative and resistant to pathways that eliminate damaged or aberrant cells, no longer divide and die. SNS-595 acts synergistically in cancer cell lines when combined with several standard chemotherapeutic agents in vitro.
In preclinical models, SNS-595 shows promising in vivo activity when combined with Ara— C, cytarabine, gemcitabine, cisplatin, and carboplatin. Additional rational combinations with SNS-595 are currently under investigation.
SNS-595 is in clinical studies of acute leukemias and platinum-resistant ovarian cancer. Clinical responses with single agent SNS-595 have been seen in these indications, as well as in non-small cell and small cell lung cancers. SNS-595 has the potential for activity as a single agent and, based on our current understanding of mechanism of action, in rational combination with other anti-cancer agents for the treatment of both advanced and earlier stage disease.
SNS-595 Presentations
Safety and Efficacy Experience of Voreloxin (formerly SNS-595) in Relapsed/Refractory Acute Leukemia Patients ≥60 years old Compared to < 60 years old: Results of a Phase 1b StudyA Phase 2 Trial of Voreloxin (Formerly SNS-595) in Women with Platinum-Resistant Epithelial Ovarian CancerEx Vivo Activity of SNS-595 Against Biopsies of Acute Myeloid Leukemia, Triple Negative Breast and Ovarian Cancers Supports Ongoing and Potential Clinical Indications
